MedTrace Logo

Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

NCT03540043 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2021-09-16

No results posted yet for this study

Summary

A Phase 2, multicenter, double-blind, placebo control study evaluating the safety and efficacy of Thykamine in adult patient suffering of mild-to-moderate Atopic Dermatitis

Conditions

  • Atopic Dermatitis Eczema

Interventions

DRUG

Administration of Placebo

Botanical Drug Phase 2 clinical study

DRUG

Administration of PUR0110 (Thykamine) 0.05%

Botanical Drug Phase 2 clinical study

DRUG

Administration of PUR0110 (Thykamine) 0.1%

Botanical Drug Phase 2 clinical study

DRUG

Administration of PUR0110 (Thykamine) 0.25%

Botanical Drug Phase 2 clinical study

Sponsors & Collaborators

  • PurGenesis Technologies Inc.

    lead INDUSTRY

Principal Investigators

  • Yves Poulin, MD · Centre de Recherche Dernatologique du Quebec

  • Wei Jing Loo, MD · DermEffects

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-23
Primary Completion
2019-12-31
Completion
2020-06-03

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03540043 on ClinicalTrials.gov